2115706-15-3Relevant articles and documents
A novel intestinal-restricted FXR agonist
Wang, Hong,Zhao, Zhou,Zhou, Jiyu,Guo, Yitong,Wang, Guangji,Hao, Haiping,Xu, Xiaowei
, p. 3386 - 3390 (2017/07/07)
In this study, a new intestinal-restricted FXR agonist named fexaramine-3 (Fex-3) was developed and investigated both in vitro and in vivo. Fex-3 could selectively activate intestinal FXR and promote the expression of BSEP and SHP while suppressing CYP7A1 which is involved in bile acids syntheses better than the reported intestinal-restricted FXR agonist fexaramine (Fex). We demonstrated that Fex-3 targeted on FXR in ileum and has better selectivity than Fex. And the study of utilizing Fex-3 to reduce obesity was undergoing.